Welcome
We believe current cancer diagnostic tests are inadequate: there is only one blood test for cancer (the PSA for prostate cancer) in common clinical use.
Volition aims to address the need for inexpensive, accurate, and scalable cancer diagnostics with its NuQ® suite of products. NuQ® is based on proprietary Nucleosomics® technology: measurement and identification of nucleosome structures in the blood.
VolitionRX Limited is quoted on the OTC Bulletin Board in the United States of America under the symbol VNRX.
|
|
Read more...
|
|
Nucleosomics®
Volition is currently developing a range of blood-based epigenetic cancer diagnostic tests, which will be released for research then clinical use in Europe, North America, and around the world. The tests:
- Detect nucleosome structures in a patient’s blood, giving an indication that cancer is present in the body; and
- Identify the qualitative differences between nucleosomes, identifying the type of cancer present - we are focusing initially on colon, pancreatic, breast and lung cancers.
|
|
Read more...
|
|
Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic
Namur, Belgium, 1 May 2013… VolitionRx Limited (OTC: VNRX), a life sciences company that is developing blood-based diagnostic tests for different types of cancer, has retained Racepoint Group as its public relations agency of record. The company’s tests are based on the science of Nucleosomics® which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
|
|
Read more...
|
|
|
